Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Adage Capital Reveals New Investment In Post-IPO TerraForm Power Inc (TERP)

Phill Gross and Robert Atchinson, the managers of Adage Capital Management, see value in TerraForm Power Inc (NASDAQ:TERP), an energy company that recently went public. As reported in a filing with the Securities and Exchange Commission, Adage Capital has initiated a new position through the acquisition of approximately 2.4 million shares. As a result, the fund has control over 8.68% of TerraForm Power Inc (NASDAQ:TERP)’s common stock.

Phill Gross Adage Capital Management

Among the hedge funds that we track, Adage Capital is the first one to invest in TerraForm Power Inc (NASDAQ:TERP). The company went public on July 17, in an Initial Public Offering (IPO) priced at $25 a share. The market welcomed the company with open arms: the stock rallied more than 35% on the debut. A total of 20 million Class A shares were offered, generating net proceedings of approximately $533.5 million. The company also issued options for the underwriters to buy up to 3 million shares at the IPO price, which were exercised in full. TerraForm Power Inc (NASDAQ:TERP) used the proceedings from the offering to repay some of its debt, to finance new solar projects and for other corporate purposes.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!